Treatment with both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for hypertension is not recommended because it is linked with a higher incidence of major kidney adverse events (Class III, LoE A) [60]. The gene discussed is ACE; the disease is hypertensive disorder.